These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1057 related items for PubMed ID: 9534098

  • 1. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [Abstract] [Full Text] [Related]

  • 2. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [Abstract] [Full Text] [Related]

  • 3. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V, Devereux RB.
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [Abstract] [Full Text] [Related]

  • 5. Left ventricular hypertrophy: a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure.
    Mansoor GA, Massie BM.
    Blood Press Monit; 1999 Jun; 4 Suppl 1():S19-22. PubMed ID: 10822413
    [Abstract] [Full Text] [Related]

  • 6. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E, Muiesan ML, Rizzoni D.
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [Abstract] [Full Text] [Related]

  • 7. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H, Li LM, Cao WH, Sun NL, Liu MZ, Hu YH.
    Ann Hum Biol; 2005 Oct; 32(1):30-43. PubMed ID: 15788353
    [Abstract] [Full Text] [Related]

  • 8. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B.
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [Abstract] [Full Text] [Related]

  • 9. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Jun; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

  • 10. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J, Delpón E, Valenzuela C.
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [Abstract] [Full Text] [Related]

  • 11. ESH-ESC guidelines for the management of hypertension.
    Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B.
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [Abstract] [Full Text] [Related]

  • 12. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C.
    Ital Heart J; 2004 Jul; 5(7):505-10. PubMed ID: 15487267
    [Abstract] [Full Text] [Related]

  • 13. Regression of left ventricular hypertrophy: do antihypertensive classes differ?
    Sheridan DJ.
    J Hypertens Suppl; 2000 Jul; 18(3):S21-7. PubMed ID: 10952084
    [Abstract] [Full Text] [Related]

  • 14. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values.
    Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, Dell'Oro R, Grassi G, Sega R, Mancia G.
    J Hypertens; 2009 Dec; 27(12):2458-64. PubMed ID: 19654559
    [Abstract] [Full Text] [Related]

  • 15. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up.
    Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E.
    J Hypertens Suppl; 1996 Dec; 14(5):S43-9. PubMed ID: 9120684
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B.
    Blood Press Suppl; 1994 Dec; 2():35-40. PubMed ID: 8061844
    [Abstract] [Full Text] [Related]

  • 17. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ, Anderson S.
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [Abstract] [Full Text] [Related]

  • 18. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA, Vyssoulis GP, Karpanou EA, Marinakis AG, Barbetseas JD, Zervoudaki AI, Cokkinos DV, Stefanadis CI.
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [Abstract] [Full Text] [Related]

  • 19. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH, Alfayoumi F.
    Prog Cardiovasc Dis; 2006 Apr; 48(5):326-41. PubMed ID: 16627048
    [Abstract] [Full Text] [Related]

  • 20. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?
    Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C.
    J Hum Hypertens; 2004 Dec; 18 Suppl 2():S23-8. PubMed ID: 15592569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.